According to Medical Developments International (MVP), Mundipharma has launched the company’s Penthrox methoxyflurane inhaler for or the treatment of moderate to severe pain in trauma patients in France and Belgium, triggering a milestone payment of $2.0 million to MVP.
Mundipharma owns the rights to Penthrox in most of Europe outside of the UK and Ireland, where Galen markets the product. In a separate press release, MVP said that Galen has “made good progress in rolling out Penthrox,” with 4 of the 11 major trauma centers in the UK now using Penthrox. The product is now being used in a total of 34 hospitals in the UK and Ireland, the company said.
MVP CEO John Sharman commented, “The launch of Penthrox in France is an exciting achievement for MVP. France represents a significant market for Penthrox within Europe and pre-launch feedback from the market is extremely positive.”
Read the MVP press release on the launch in France and Belgium.
Read the MVP press release on the UK/Ireland status.
